Details
Stereochemistry | ACHIRAL |
Molecular Formula | C9H6I3NO3 |
Molecular Weight | 556.8623 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(=O)NC1=C(I)C=C(I)C(C(O)=O)=C1I
InChI
InChIKey=GNOGSFBXBWBTIG-UHFFFAOYSA-N
InChI=1S/C9H6I3NO3/c1-3(14)13-8-5(11)2-4(10)6(7(8)12)9(15)16/h2H,1H3,(H,13,14)(H,15,16)
Molecular Formula | C9H6I3NO3 |
Molecular Weight | 556.8623 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.drugs.com/pro/gastrografin.htmlCurator's Comment: description was created based on several sources, including
http://www.tabletwise.com/brazil/urografina-solution | https://clinicaltrials.gov/ct2/show/NCT01440712 | https://clinicaltrials.gov/ct2/show/NCT01515696 | https://clinicaltrials.gov/ct2/show/NCT00601809
Sources: https://www.drugs.com/pro/gastrografin.html
Curator's Comment: description was created based on several sources, including
http://www.tabletwise.com/brazil/urografina-solution | https://clinicaltrials.gov/ct2/show/NCT01440712 | https://clinicaltrials.gov/ct2/show/NCT01515696 | https://clinicaltrials.gov/ct2/show/NCT00601809
Acetrizoic acid (trade names Gastrografina, Urografina in Portugal) is a palatable lemon-flavored water-soluble iodinated radiopaque X-ray contrast medium for oral or rectal administration only. Acetrizoic acid is indicated for radiographic examination of segments of the gastrointestinal tract (esophagus, stomach, proximal small intestine, and colon). The preparation is particularly indicated when a more viscous agent such as barium sulfate, which is not water-soluble, is not feasible or is potentially dangerous. Administration of hypertonic Gastrografin solutions may lead to hypovolemia and hypotension due to fluid loss from the intestine.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1697668 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23571415 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Diagnostic | Gastrografina Approved UseUnknown |
|||
Diagnostic | Gastrografina Approved UseUnknown |
|||
Diagnostic | Gastrografina Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
248 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2524207/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
ACETRIZOIC ACID plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
416 ng/mL |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
ACETRIZOIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1342 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2524207/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
ACETRIZOIC ACID plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2524207/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
ACETRIZOIC ACID plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.1% |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
ACETRIZOIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/dosage/gastrografin.html
Adult oral dosage may range from 30 to 90 mL (11 to 33 g iodine), depending on the nature of the examination and the size of the patient. For infants and children less than 5 years of age, 30 mL (11 g iodine) are usually adequate; for children 5 to 10 years of age, the suggested dose is 60 mL (22 g iodine).
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/4724805
Blood was taken from the femoral artery of heparinized dogs (heparin 500 I.U./kg I.V.). Immediately after collection, the blood samples were incubated for 45 sec. at 37 C with the solutions of the ACETRIZOIC ACID;the final concentrations of the contrast media in the incubation medium were 220 mM. This was done by adding to aliquots of whole blood the solutions oЈ contrast media, which were hyperosmolar to plasma (2200 mOsm).
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 14:59:15 GMT 2023
by
admin
on
Fri Dec 15 14:59:15 GMT 2023
|
Record UNII |
24256BQV7M
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QV08AA07
Created by
admin on Fri Dec 15 14:59:16 GMT 2023 , Edited by admin on Fri Dec 15 14:59:16 GMT 2023
|
||
|
WHO-ATC |
V08AA07
Created by
admin on Fri Dec 15 14:59:16 GMT 2023 , Edited by admin on Fri Dec 15 14:59:16 GMT 2023
|
||
|
NCI_THESAURUS |
C390
Created by
admin on Fri Dec 15 14:59:16 GMT 2023 , Edited by admin on Fri Dec 15 14:59:16 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID2022549
Created by
admin on Fri Dec 15 14:59:16 GMT 2023 , Edited by admin on Fri Dec 15 14:59:16 GMT 2023
|
PRIMARY | |||
|
CHEMBL1201327
Created by
admin on Fri Dec 15 14:59:16 GMT 2023 , Edited by admin on Fri Dec 15 14:59:16 GMT 2023
|
PRIMARY | |||
|
201-600-7
Created by
admin on Fri Dec 15 14:59:16 GMT 2023 , Edited by admin on Fri Dec 15 14:59:16 GMT 2023
|
PRIMARY | |||
|
24256BQV7M
Created by
admin on Fri Dec 15 14:59:16 GMT 2023 , Edited by admin on Fri Dec 15 14:59:16 GMT 2023
|
PRIMARY | |||
|
m994
Created by
admin on Fri Dec 15 14:59:16 GMT 2023 , Edited by admin on Fri Dec 15 14:59:16 GMT 2023
|
PRIMARY | Merck Index | ||
|
ACETRIZOIC ACID
Created by
admin on Fri Dec 15 14:59:16 GMT 2023 , Edited by admin on Fri Dec 15 14:59:16 GMT 2023
|
PRIMARY | |||
|
C83516
Created by
admin on Fri Dec 15 14:59:16 GMT 2023 , Edited by admin on Fri Dec 15 14:59:16 GMT 2023
|
PRIMARY | |||
|
100000078808
Created by
admin on Fri Dec 15 14:59:16 GMT 2023 , Edited by admin on Fri Dec 15 14:59:16 GMT 2023
|
PRIMARY | |||
|
758681
Created by
admin on Fri Dec 15 14:59:16 GMT 2023 , Edited by admin on Fri Dec 15 14:59:16 GMT 2023
|
PRIMARY | |||
|
6806
Created by
admin on Fri Dec 15 14:59:16 GMT 2023 , Edited by admin on Fri Dec 15 14:59:16 GMT 2023
|
PRIMARY | |||
|
DB09347
Created by
admin on Fri Dec 15 14:59:16 GMT 2023 , Edited by admin on Fri Dec 15 14:59:16 GMT 2023
|
PRIMARY | |||
|
63
Created by
admin on Fri Dec 15 14:59:16 GMT 2023 , Edited by admin on Fri Dec 15 14:59:16 GMT 2023
|
PRIMARY | |||
|
SUB00256MIG
Created by
admin on Fri Dec 15 14:59:16 GMT 2023 , Edited by admin on Fri Dec 15 14:59:16 GMT 2023
|
PRIMARY | |||
|
85-36-9
Created by
admin on Fri Dec 15 14:59:16 GMT 2023 , Edited by admin on Fri Dec 15 14:59:16 GMT 2023
|
PRIMARY | |||
|
D000100
Created by
admin on Fri Dec 15 14:59:16 GMT 2023 , Edited by admin on Fri Dec 15 14:59:16 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |